Douglas J Watson
Overview
Explore the profile of Douglas J Watson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riedl M, Banerji A, Manning M, Burrell E, Joshi N, Patel D, et al.
Orphanet J Rare Dis
. 2018 Oct;
13(1):180.
PMID: 30314518
Background: Real-world data on usage and associated outcomes with hereditary angioedema (HAE)-specific medications introduced to the United States (US) market since 2009 are very limited. The purpose of this retrospective...
2.
Lumry W, Craig T, Zuraw B, Longhurst H, Baker J, Li H, et al.
J Allergy Clin Immunol Pract
. 2018 Feb;
6(5):1733-1741.e3.
PMID: 29391286
Background: Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) impairs health-related quality of life (HRQoL). Objective: The objective of this study was to assess HRQoL outcomes in patients self-administering subcutaneous C1-INH (C1-INH[SC];...
3.
Martinez C, Watson D, Shebl A, Wallenhorst C, Hubsch A, Simon T
Am J Hematol
. 2017 Oct;
93(1):E17-E20.
PMID: 28983941
No abstract available.
4.
Riedl M, Banerji A, Busse P, Johnston D, Davis-Lorton M, Patel S, et al.
Ann Allergy Asthma Immunol
. 2017 Jul;
119(1):59-64.
PMID: 28668241
Background: Hereditary angioedema (HAE) is a rare genetic disorder with substantial morbidity and mortality. Despite expanded choices for effective acute treatment, prophylactic options are more limited. Intravenous C1 esterase inhibitor...
5.
Taylor W, Redden D, Dalbeth N, Schumacher H, Edwards N, Simon L, et al.
J Rheumatol
. 2014 Jan;
41(3):574-80.
PMID: 24429178
Objective: To determine the extent to which instruments that measure core outcome domains in acute gout fulfill the Outcome Measures in Rheumatology (OMERACT) filter requirements of truth, discrimination, and feasibility....
6.
Taylor S, Everett S, Taylor T, Watson D, Taylor-Stokes G
Open Access Rheumatol
. 2013 Jul;
5:69-76.
PMID: 27790025
Purpose: The clinical response to traditional nonsteroidal anti-inflammatory drugs (tNSAIDs) varies substantially. The objective of this study was to describe physicians' and patients' perceptions of response to tNSAIDs as measured...
7.
Cai B, Xu W, Bortnichak E, Watson D
Pharmacoepidemiol Drug Saf
. 2012 May;
21(7):770-774.
PMID: 22544805
PURPOSE: To identify practices common to both the General Practice Research Database and The Health Improvement Network database for purposes of combining the databases for analysis without duplicate records. METHODS:...
8.
Arden N, Hauber A, Mohamed A, Reed Johnson F, Peloso P, Watson D, et al.
J Rheumatol
. 2012 Mar;
39(5):1056-63.
PMID: 22422497
Objective: To quantify the relative importance that UK physicians attach to the benefits and risks of current drugs when making treatment decisions for patients with osteoarthritis (OA). Methods: Physicians treating...
9.
Stauffer M, Taylor S, Watson D, Peloso P, Morrison A
Int J Inflam
. 2011 Jul;
2011:231926.
PMID: 21755025
Our objective was to develop a working definition of nonresponse to analgesic treatment of arthritis, focusing on the measurement of pain on the 0-100 mm pain visual analog scale (VAS)....
10.
Crowe B, Xia H, Berlin J, Watson D, Shi H, Lin S, et al.
Clin Trials
. 2009 Oct;
6(5):430-40.
PMID: 19846894
Background: The Safety Planning, Evaluation and Reporting Team (SPERT) was formed in 2006 by the Pharmaceutical Research and Manufacturers of America. Purpose: SPERT's goal was to propose a pharmaceutical industry...